Navigation Links
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

ubject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of

operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
2. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
6. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
11. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
(Date:8/27/2015)... 2015 Major pharmaceutical and medical device companies and ... in Philadelphia on Oct. 20, discussing ... Hagy of HB Litigation Conferences has announced. ... at http://litigationconferences.com/?p=31886 The program is co-chaired ... Mahoney and Michelle Hart Yeary of Dechert LLP. ...
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Services is pleased to announce the exciting addition of ... the new Manager of Minerals.  Dr. Al-Ammar brings with ... has over fourteen years of experience with ICP-MS and ... United States and Europe.  Additionally, Dr. Al-Ammar has seven ...
... 15, 2011 PPTA opposes New Jersey Assembly Bill 2003 ... 13 that imposes a new tax on therapies used to ... The Bleeding Disorders Treatment Fund by taxing the manufacturers of ... rebate. PPTA opposes any policy that would impose a tax ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2PPTA Opposes Tax on Blood Clotting Factor 2
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... river is in the news again, for all the wrong ... York state are warning boaters and others who use the ... million gallons of raw sewage that reached the river after ... health concern would be for anyone coming in contact with ...
... alarm for parents about a common myth: that children dont ... so-called brain attacks each year, and half of them end ... ,Strokes in children may occur even more ... sadly, strokes in children are sometimes not recognized and treated, ...
... a one-year-old child having his foot amputated has moved ... an explanation. ,In January, a fractured leg brought ... his limb was plastered below the waist. However, the skin ... necessitating its surgical separation on March 5. ,A ...
... boys affected by Duchenne muscular dystrophy. A new study has found ... their own for a longer period of time and reduce their ... in 3,500 boys. Symptoms start in early childhood and rapidly progress ... and 11. There is no cure for the disorder. ...
... Former US president Bill Clinton has once again lent a ... fallout between the Brazil government and drug giant Merck ... diffuse the situation. Clinching a deal with two Indian pharmaceutical ... the companies to provide second-line AVR drugs and a next ...
... prescribed a drug that reduces their estrogen levels. But ... is widespread concern about how the estrogen-reducing drugs - ... ,A study at Washington University School of Medicine in ... aromatase inhibitors, and researchers are calling for interested women ...
Cached Medicine News:Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:Court Seeks Explanation from Hospital for Childs Amputation 2Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2Health News:Clinton Foundation Eases Over-Pricing Of AIDS Drugs Once More 2Health News:Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: